Reading this article from Breastcancer.org along with the FDA’s press release and a viewpoint by cancer writer Elaine Schattner, provides three perspectives and good context for women with BRCA+ metastatic breast cancer wondering if Lynparza is right for them.
- Breastcancer.org: Lynparza Approved for Metastatic HER2-Negative BRCA+ Breast Cancer
- FDA: FDA Approves First Treatment for Metastatic BRCA Breast Cancer
- Elaine Schattner’s viewpoint: PARP Drugs Like Lynparaza May Help Some
- Metastatic Trial Search: Find Clinical Trials for BRCA1/2 Metastatic Breast Cancer
Last Modified on February 25, 2021